Phase 2 N=8 A Phase II Trial If Nivolumab, Lenalidomide and Dexamethasone in High Risk Smoldering Myeloma
Smoldering Multiple Myeloma
Primary: 2 Year Progression Free Percent — 62.5 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=55 Carfilzomib, Lenalidomide, and Dexamethasone for Smoldering Multiple Myeloma
Multiple Myeloma
Primary: Percentage of Participants With Minimal Residual Disease (MRD)Negative Complete Response (CR) Per International Myeloma Working Group (IMWG) Criteria — 70.4 percentage…
Phase 2 N=20 Denosumab for Smoldering Multiple Myeloma
Smoldering Multiple Myeloma
Primary: Proportion of Subjects With a Downgraded Risk of Progression of Smoldering Multiple Myeloma if the Risk Category Decreases. — 0 proportion of participants
Phase 2 N=51 E-PRISM: Phase II Trial of Elotuzumab Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma
Smoldering Myeloma · Smoldering Multiple Myeloma
Primary: Percent of Patients Who Are Progression Free at 2 Years — 45.0; 36.4 percentage of participants
Phase 2 N=85 A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma
High-risk Smoldering Multiple Myeloma
Primary: One-Year Progression-Free Survival (PFS) Rate — 84.5; 74.4 Percentage of participants
Phase 2 N=31 Biomarker Study of Elotuzumab in High Risk Smoldering Myeloma
Smoldering Multiple Myeloma
Primary: Linear Regression of Maximal Percent Reduction in Serum Monoclonal (M) Protein on Baseline Percent CD56^Dim Cells in Bone Marrow — -2.562; 2.464; 0.274 % chg from BL in…
Phase 2 N=61 Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple Myeloma
Smoldering Multiple Myeloma
Primary: Proportion Of High Risk SMM Patients Who Are Progression Free 2 Years After Receiving IRD Combination Therapy — 50 Participants
Phase 2 N=18 Celgene High Risk Multiple Myeloma (MM) Revlimid Induction and Maintenance Therapy
Multiple Myeloma
Primary: Progression Free Survival — 3; 9 participants
Phase 2 N=30 Study on the Anti-tumor Activity, Safety and Pharmacology of IPH2101 in Patients With Smoldering Multiple Myeloma
Smoldering Multiple Myeloma
Primary: Rate of Patients Achieving an Objective Response — 0; 0 participants
Phase 2 N=67 Lenalidomide (Revlimid®) Plus Low-dose Dexamethasone (Ld x 4 Cycles) Then Stem Cell Collection Followed by Randomization to Continued Ld or Stem Cell Transplantation (SCT) Plus Maintenance L
Multiple Myeloma
Primary: Progression Free Survival (PFS) Rate at 2 Years After Enrollment in Untreated Patients With Multiple Myeloma. — 84.6; 83.3 percentage of participants
Phase 2 N=123 Monoclonal Antibody-Based Sequential Therapy for Deep Remission in Multiple Myeloma
Multiple Myeloma
Primary: Percentage of Patients With MRD(-) Remissions at the Completion of Consolidation Therapy — 81.4 percentage of patients achieving MRD (-)
Phase 2 N=71 Pomalidomide in Gene Expression Profiling (GEP)-Defined High-risk Multiple Myeloma
Multiple Myeloma
Primary: Progression-free Survival (PFS) After Initiation of Pomalidomide Therapy — 13 percentage of participants
Phase 2 N=31 Imaging in MGUS, SMM and MM
Multiple Myeloma · Smoldering Multiple Myeloma · Monoclonal Gammopathy of Undetermined Significance
Primary: Count of Participants With Positive and Negative 18F-FDG PET CT and F18-NaF PET CT Imaging Results in Individuals With MGUS, SMM, and MM. — 0; 1; 5; 10 Participants
Phase 2 N=54 Melphalan and Radiation Therapy Followed By Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Stage I, Stage II, or Stage III Multiple Myeloma
Refractory Multiple Myeloma · Smoldering Multiple Myeloma · Stage I Multiple Myeloma
Primary: Maximum Tolerated Dose (MTD) — 1600 cGy
Phase 2 N=60 Lenalidomide and High Dose Melphalan Followed by Autologous Stem Cell Transplant in Multiple Myeloma
Multiple Myeloma
Primary: Phase I: Number of Patients With Dose Limiting Toxicity — 0; 0; 0; 0 Participants
Phase 2 N=21 Rituximab and Cyclophosphamide in Treating Patients With High Risk, Refractory, or Relapsed Multiple Myeloma
Multiple Myeloma and Plasma Cell Neoplasm
Primary: Event-free Survival — 29 percentage of participants
Phase 2 N=6 S1211 Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma
DS Stage I Plasma Cell Myeloma · DS Stage II Plasma Cell Myeloma · DS Stage III Plasma Cell Myeloma
Primary: Phase I: Maximum Tolerated Dose (MTD) of Elotuzumab in Combination With Bortezomib, Lenalidomide and Dexamethasone — 10 mg/kg (Phase II dosing for elotuzumab)
Phase 2 N=102 High-Dose Sequential Therapy and Single Autologous Transplantation for Multiple Myeloma
Multiple Myeloma
Primary: Number of Participants With Pulmonary Toxicity — 32 Participants
Phase 2 N=32 Autologous or Syngeneic Stem Cell Transplant Followed by Donor Stem Cell Transplant and Bortezomib in Treating Patients With Newly Diagnosed High-Risk, Relapsed, or Refractory Multiple Myeloma
Refractory Plasma Cell Myeloma
Primary: Number of Patients Surviving Progression-free — 14 Participants
Phase 1 N=12 TMI With HD Mel in ASCT for R/R Multiple Myeloma (BMT-03)
Multiple Myeloma, Relapsed · Multiple Myeloma, Refractory to Standard Treatment
Primary: Maximum Tolerated Dose (MTD) of Gy — NA Participants
Phase 2 N=50 Lenalidomide/Bortezomib/Dexamethasone for Multiple Myeloma (MM)
Multiple Myeloma
Primary: Objective Response Rate — 6; 16; 11; 10 Participants
Phase 2 N=23 Celecoxib in Preventing Multiple Myeloma in Patients With Monoclonal Gammopathy or Smoldering Myeloma
Monoclonal Gammopathy of Undetermined Significance · Multiple Myeloma · Smoldering Multiple Myeloma
Primary: Changes in M-protein Levels — 1.65; 2.24 g/dL — p=.23
Phase 2 N=41 Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma
Extramedullary Plasmacytoma · Isolated Plasmacytoma of Bone · Light Chain Deposition Disease
Primary: Median Progression Free Survival (mPFS) — 76.4 months
Phase 2 N=16 Lenalidomide and High-Dose Melphalan
Myeloma · Stem Cell Transplantation
Primary: Maximum Tolerated Dose (MTD) of Lenalidomide — 100 mg/day
Phase 2 N=43 Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302)
Multiple Myeloma
Primary: Percentage of Participants With Progression-Free Survival — 65.3; 72.7; 55.3; 59.1 percentage of participants — p=1.0
Phase 2 N=75 High-Dose Gemcitabine, Busulfan and Melphalan With Hematopoietic-Cell Support for Patients With Poor-Risk Myeloma
Myeloma
Primary: Participants Who Had Measurable Disease at Time of Transplant and Achieved a Stringent Complete Remission — 16 Participants
Phase 2 N=25 SMAC Mimetic LCL161 Alone or With Cyclophosphamide in Treating Patients With Relapsed or Refractory Multiple Myeloma
Recurrent Plasma Cell Myeloma · Refractory Plasma Cell Myeloma
Primary: Confirmed Overall Response Rate (Stringent Complete Response [sCR], Complete Response [CR], Very Good Partial Response [VGPR], or Partial Response [PR]) With Single…
Phase 3 N=47 Trial of Three Stem Cell Mobilization Regimens for Multiple Myeloma
Multiple Myeloma
Primary: Number of Patients Able to Collect >=6 x 106 CD34+ Cells/kg in <= 2 Collections. — 11; 0; 14 Participants — p=0.90
Phase 2 N=20 Chemotherapy, Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple Myeloma
Multiple Myeloma
Primary: Immune Response — 7 Particpants
Phase 2 N=13 Sorafenib and Bortezomib Treatment for Relapsed or Refractory Multiple Myeloma Patients
Multiple Myeloma
Primary: Objective Response Rate (ORR), the Percentage of Patients Who Experience an Objective Benefit From Treatment — 15 percentage of participants